Sort by
Items per page

Send to

Choose Destination

Best matches for abacavir sulfate AND antiretroviral therapy, highly active AND cd4 count determination procedure AND efavirenz:

Search results

Items: 1 to 20 of 39


First-line antiretroviral drug discontinuations in children.

Fortuin-de Smidt M, de Waal R, Cohen K, Technau KG, Stinson K, Maartens G, Boulle A, Igumbor EU, Davies MA.

PLoS One. 2017 Feb 13;12(2):e0169762. doi: 10.1371/journal.pone.0169762. eCollection 2017.


Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.

Raffi F, Rachlis A, Brinson C, Arasteh K, Górgolas M, Brennan C, Pappa K, Almond S, Granier C, Nichols WG, Cuffe RL, Eron J Jr, Walmsley S.

AIDS. 2015 Jan 14;29(2):167-74. doi: 10.1097/QAD.0000000000000519.


48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, Stephens J, Nichols G.

PLoS One. 2014 Sep 4;9(9):e105653. doi: 10.1371/journal.pone.0105653. eCollection 2014. Review.


French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.

Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L'Hénaff M, Persiaux R, Rey D, Rouzioux C, Taburet AM, Morlat P; 2013 French HIV expert group.

J Int AIDS Soc. 2014 Jun 17;17:19034. doi: 10.7448/IAS.17.1.19034. eCollection 2014.


Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virus.

Tau P, Mancon A, Mileto D, Di Nardo Stuppino S, Bottani G, Gismondo MR, Galli M, Micheli V, Rusconi S.

AIDS Res Hum Retroviruses. 2014 May;30(5):480-3. doi: 10.1089/AID.2013.0264. Epub 2013 Dec 31.


Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.

HIV Med. 2013 Oct;14(9):571-7. doi: 10.1111/hiv.12044. Epub 2013 May 13.


Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.

Gianotti N, Galli L, Bocchiola B, Cahua T, Panzini P, Zandonà D, Salpietro S, Maillard M, Danise A, Pazzi A, Lazzarin A, Castagna A.

HIV Med. 2013 Mar;14(3):153-60. doi: 10.1111/j.1468-1293.2012.01046.x. Epub 2012 Sep 20.


Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies.

Manfredi R, Piergentili B, Marinacci G, Calza L.

Int J STD AIDS. 2012 Mar;23(3):e35-8. doi: 10.1258/ijsa.2009.009136.


Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen.

Chini M, Tsoupras AB, Mangafas N, Tsogas N, Papakonstantinou VD, Fragopoulou E, Antonopoulou S, Gargalianos P, Demopoulos CA, Lazanas MC.

Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):247-58.


Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.

Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, Mohapi L, Short W, Crauwels H, Vanveggel S, Boven K.

HIV Med. 2012 Aug;13(7):406-15. doi: 10.1111/j.1468-1293.2012.00991.x. Epub 2012 Mar 14.


Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2011 Oct 15;204(8):1191-201. doi: 10.1093/infdis/jir505.


Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

Brogan AJ, Talbird SE, Cohen C.

Value Health. 2011 Jul-Aug;14(5):657-64. doi: 10.1016/j.jval.2011.01.009. Epub 2011 Jun 12.


Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.

Goebel FD, MacGregor TR, Sabo JP, Castles M, Johnson PA, Legg D, McCallister S.

HIV Clin Trials. 2010 Jan-Feb;11(1):28-38. doi: 10.1310/hct1101-28.


Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.

Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63. Erratum in: J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):529.


Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA; International AIDS Society-USA.

JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.


[Pilot study of antiretroviral therapy in Djibouti].

Ahmed AA, Latoundji S.

East Mediterr Health J. 2007 Nov-Dec;13(6):1274-85. French.


First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.

Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; French Hospital Database on HIV, ANRS C04.

Antivir Ther. 2007;12(3):317-24.


Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.

Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR.

AIDS. 2007 Apr 23;21(7):813-23.


Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.

Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW.

Pediatrics. 2007 Mar;119(3):e705-15. Epub 2007 Feb 16.


Supplemental Content

Loading ...
Support Center